Triple negative breast cancer (TNBC) is a highly aggressive, heterogeneous disease with high rates of metastasis and poor prognosis. Currently, there are no targeted therapies for TNBC and adjuvant chemotherapy is the mainstay treatment. Identification of molecular targets and potent combination therapies for TNBC is a major challenge of extensive biomedical research and our own studies. Given that drug resistance is a critical clinical problem, a drug combination that could overcome drug resistance could offer a promising therapeutic opportunity. We have recently identified potent combination therapies for TNBC which are not only potent but could also overcome drug resistance and further defined the molecular mechanisms underlying their therapeutic benefit.
